Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) EBT (2018 - 2025)

Entera Bio has reported EBT over the past 8 years, most recently at -$3.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 29.22% year-over-year to -$3.0 million, compared with a TTM value of -$11.5 million through Dec 2025, down 20.06%, and an annual FY2025 reading of -$11.4 million, down 20.07% over the prior year.
  • EBT came in at -$3.0 million for Q4 2025, up from -$3.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$2.0 million in Q4 2023 to a low of -$4.1 million in Q4 2021.
  • Median EBT over the past 5 years was -$2.6 million (2021), compared with a mean of -$2.8 million.
  • The largest YoY upside for EBT was 78.26% in 2021 against a maximum downside of 298.71% in 2021.
  • Over 5 years, EBT stood at -$4.1 million in 2021, then increased by 25.13% to -$3.1 million in 2022, then skyrocketed by 35.25% to -$2.0 million in 2023, then dropped by 17.49% to -$2.3 million in 2024, then decreased by 29.22% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's EBT are -$3.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$2.7 million (Q2 2025).